TrialAdvances in therapy2025

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Firsekibart, an Anti-interleukin-1β Monoclonal Antibody, in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.

Hongzhong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.